Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX.
Liao MZ, Deng R, Gibiansky L, Lu T, Agarwal P, Dere R, Lee C, Hirata J, Herbaux C, Salles G, Li C, Miles D. Liao MZ, et al. Among authors: herbaux c. Clin Transl Sci. 2023 Dec;16(12):2744-2755. doi: 10.1111/cts.13669. Epub 2023 Oct 31. Clin Transl Sci. 2023. PMID: 37864313 Free PMC article.
Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells.
Camus V, Houot R, Brisou G, Tessoulin B, Bailly S, Sesques P, Decroocq J, Krzisch D, Obéric L, Lemonnier F, Bouabdallah K, Campidelli A, Tounes L, Abraham J, Herbaux C, Morschhauser F, Damaj G, Guidez S, Carras S, Fornecker LM, Choquet S, Hermine O, Paillassa J, Chauchet A, Casasnovas O, Drieu La Rochelle L, Castilla-Llorente C, Joris M, Dupont V, Marquet A, Le Gouill S, Jardin F. Camus V, et al. Among authors: herbaux c. Blood Adv. 2024 Aug 20:bloodadvances.2024013726. doi: 10.1182/bloodadvances.2024013726. Online ahead of print. Blood Adv. 2024. PMID: 39163620
Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.
Herbaux C, Bret C, Bachy E, Bories P, Di Blasi R, Cuffel A, Gastinne T, Lamy T, Roussel M, Bouabdallah K, Beauvais D, Cartron G, Bay JO, Blaise D, Rubio MT, Mohty M, Le Bras F, Casasnovas O, Guy J, Guidez S, Llorente CC, Hermine O, La Rochelle LD, Carras S, Guffroy B, Caillat-Zucman S, Houot R, Le Gouill S. Herbaux C, et al. Haematologica. 2024 Jun 20. doi: 10.3324/haematol.2023.284786. Online ahead of print. Haematologica. 2024. PMID: 38899352 Free article.
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
Laribi K, Poulain S, Willems L, Merabet F, Herbaux C, Roos-Weil D, Laribi de Materre I, Roussel X, Nudel M, Tricot S, Dupuis J, Le Calloch R, Bareau B, Leblond V. Laribi K, et al. Among authors: herbaux c. Br J Haematol. 2024 Jun;204(6):2233-2236. doi: 10.1111/bjh.19409. Epub 2024 Mar 19. Br J Haematol. 2024. PMID: 38504454
Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.
Bruyer A, Dutrieux L, de Boussac H, Martin T, Chemlal D, Robert N, Requirand G, Cartron G, Vincent L, Herbaux C, Lutzmann M, Bret C, Pasero P, Moreaux J, Ovejero S. Bruyer A, et al. Among authors: herbaux c. Front Oncol. 2023 Dec 6;13:1271847. doi: 10.3389/fonc.2023.1271847. eCollection 2023. Front Oncol. 2023. PMID: 38125947 Free PMC article.
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.
Lemoine J, Bachy E, Cartron G, Beauvais D, Gastinne T, Di Blasi R, Rubio MT, Guidez S, Mohty M, Casasnovas RO, Joris M, Castilla-Llorente C, Haioun C, Hermine O, Loschi M, Carras S, Bories P, Fradon T, Herbaux C, Sesques P, Le Gouill S, Morschhauser F, Thieblemont C, Houot R. Lemoine J, et al. Among authors: herbaux c. Blood Adv. 2023 Nov 14;7(21):6589-6598. doi: 10.1182/bloodadvances.2023010624. Blood Adv. 2023. PMID: 37672383 Free PMC article.
92 results